Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Cowen Health Care Conference Transcript

Mar 06, 2023 / 06:30PM GMT
Release Date Price: R$54.9 (-0.69%)
Unidentified Analyst

At the Cowen conference again this year. Representing the company is Mike Mason, who is President of Lilly Diabetes. So Mike, thank you for making the journey. Lots to cover, obviously, an incredibly exciting business within Lilly. And so let's start right out.

Questions & Answers

Unidentified Analyst

We're all kind of fixated on the obesity opportunity -- and just how big it could be. What are the biggest challenges and barriers to growing obesity treatment in this country and outside the country?

Michael B. Mason
Eli Lilly and Company - Senior VP & President of Lilly Diabetes

All right. Well, thanks for the question. Good to see everyone. We're all packed into a tight room, hopefully, no one has COVID or we'll all have it. But, yes, I know everyone here is excited about obesity and trying to figure out the size of it. Obviously, we're doing the same thing at Lilly and trying to make it as massive an opportunity to help as many patients as possible. It is a chronic disease that really affects

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot